All stages of the HCV life cycle are potential targets, however targeting the HCV NS3–4A serine protease, NS5A and the NS5B RNA-dependent RNA polymerase are most clinically advanced. DAAs ...

In recent surveys conducted for Atea, US healthcare providers report a high likelihood of prescribing the regimen of bemnifosbuvir and ruzasvir, if approved, and US payors are receptive to inclusion ...

but no prior treatment with an HCV NS3/4A protease inhibitor or NS5A inhibitor; (genotype 3): treat for 16 weeks if previously treated with regimens containing PEG-IFN, ribavirin, and/or ...